Finanzen von Veru Inc (VERU)VERUVeru Inc

Veru Inc. (VERU) generates its revenue primarily from FC2, which accounts for 100.0% of total sales, equivalent to $6.66M. Understanding this concentration is critical for investors evaluating how VERU navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Veru Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.54%, provide a clear picture of how effectively VERU converts its operational activities into shareholder value.

In the context of the broader market, VERU competes directly with industry leaders such as GRCE and MGX. With a market capitalization of $46.55M, it holds a leading position in the sector. When comparing efficiency, VERU's gross margin of N/A stands against GRCE's N/A and MGX's 100.00%. Such benchmarking helps identify whether Veru Inc. is trading at a premium or discount relative to its financial performance.

Veru's financial performance shows a net loss of $7.0 million for Q3 2026, an improvement from the previous year, indicating effective cost management. The forward P/E ratio is 117.65, reflecting high expectations despite current losses.